Perimenopause and psychedelic research converge around hormonal change, mood symptoms, and the need for more targeted studies on treatment, safety, and lived experience

Perimenopause sits at the intersection of hormonal fluctuation, mood disruption, and growing interest in psychedelic care, raising questions about whether current research adequately reflects midlife physiology and mental health needs. Shifting estrogen and progesterone levels can affect sleep, anxiety, depression, cognition, and stress sensitivity, which may in turn shape psychedelic response, dosing, and integration needs. Psychedelic research has largely centered on broader adult populations rather than people specifically moving through perimenopause, leaving major gaps around efficacy, safety, and trial design. More targeted work could clarify how changing endocrine conditions interact with psychedelic therapy, what symptom clusters might be most relevant, and how clinicians can better support midlife patients. Clinical relevance extends beyond symptom relief alone because perimenopause often carries social, relational, and identity changes alongside physical and psychological strain. Better inclusion of this population could improve treatment precision, reduce blind spots in mental health research, and connect psychedelic medicine more directly to a common but underexamined stage of life.